IN2014DN07920A - - Google Patents

Info

Publication number
IN2014DN07920A
IN2014DN07920A IN7920DEN2014A IN2014DN07920A IN 2014DN07920 A IN2014DN07920 A IN 2014DN07920A IN 7920DEN2014 A IN7920DEN2014 A IN 7920DEN2014A IN 2014DN07920 A IN2014DN07920 A IN 2014DN07920A
Authority
IN
India
Prior art keywords
cystathionine
cbs
synthase
purification
prepared therefrom
Prior art date
Application number
Other languages
English (en)
Inventor
Richard G Carrillo
Jan P Kraus
Thomas Majtan
David Naveh
Original Assignee
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado filed Critical Univ Colorado
Publication of IN2014DN07920A publication Critical patent/IN2014DN07920A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3823Affinity chromatography of other types, e.g. avidin, streptavidin, biotin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/01Hydro-lyases (4.2.1)
    • C12Y402/01022Cystathionine beta-synthase (4.2.1.22)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN7920DEN2014 2012-03-26 2013-03-25 IN2014DN07920A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Publications (1)

Publication Number Publication Date
IN2014DN07920A true IN2014DN07920A (pt) 2015-05-01

Family

ID=49212017

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7920DEN2014 IN2014DN07920A (pt) 2012-03-26 2013-03-25

Country Status (11)

Country Link
US (4) US9243239B2 (pt)
EP (3) EP3569706A1 (pt)
JP (3) JP6146934B2 (pt)
CN (1) CN104540940B (pt)
AU (1) AU2013240003B2 (pt)
BR (1) BR112014023570B1 (pt)
CA (1) CA2867719C (pt)
HK (1) HK1246350B (pt)
IL (2) IL234635B (pt)
IN (1) IN2014DN07920A (pt)
WO (1) WO2013148580A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
IL302198A (en) * 2015-11-09 2023-06-01 Univ Colorado Regents Preparations and methods for the treatment of excessive homocysteine in the urine
WO2018195006A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
WO2020264061A1 (en) * 2019-06-25 2020-12-30 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
US20220265835A1 (en) * 2019-06-26 2022-08-25 The Regents Of The University Of Colorado, A Body Corporate Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
AU2011212885B2 (en) 2010-02-04 2015-10-01 Aemase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Also Published As

Publication number Publication date
JP2020000259A (ja) 2020-01-09
US20200131497A1 (en) 2020-04-30
EP2831229B1 (en) 2017-10-18
JP6146934B2 (ja) 2017-06-21
CA2867719C (en) 2020-08-11
EP2831229A1 (en) 2015-02-04
EP3263701B1 (en) 2019-06-19
US9243239B2 (en) 2016-01-26
BR112014023570A2 (pt) 2021-06-01
IL263162B (en) 2019-11-28
JP6952361B2 (ja) 2021-10-20
JP6839595B2 (ja) 2021-03-10
US20160177287A1 (en) 2016-06-23
US20190055537A1 (en) 2019-02-21
EP3263701A1 (en) 2018-01-03
CN104540940A (zh) 2015-04-22
CN104540940B (zh) 2018-03-06
CA2867719A1 (en) 2013-10-03
JP2015512639A (ja) 2015-04-30
BR112014023570B1 (pt) 2022-03-15
EP3569706A1 (en) 2019-11-20
AU2013240003A1 (en) 2014-10-02
HK1246350B (zh) 2020-05-15
JP2017121255A (ja) 2017-07-13
US10160962B2 (en) 2018-12-25
US10941392B2 (en) 2021-03-09
EP2831229B8 (en) 2018-10-17
IL263162A (en) 2018-12-31
US20130251700A1 (en) 2013-09-26
AU2013240003B2 (en) 2018-04-19
IL234635B (en) 2018-12-31
WO2013148580A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
AU2016204248A1 (en) Boron-Containing Molecules
IN2014DN07920A (pt)
IN2014DN08481A (pt)
IN2015DN00127A (pt)
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
EP2742126A4 (en) COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF VANILLIN OR VANILLIN BETA-D-GLUCOSIDE
GEP20196964B (en) Pest control composition including novel iminopyridine derivative
MY168300A (en) Pharmaceutical Composition for Inhalation
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
AU2013337247A8 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
SG11201405578TA (en) Pharmaceutical composition containing peptide
EP3022291A4 (en) Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IN2014DN08412A (pt)
WO2014068586A3 (en) Solid oral compositions of tolvaptan
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
IN2015DN03132A (pt)
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IN2014DN07103A (pt)
ZA201303024B (en) Nasal compositions of vitamin b12
MY165088A (en) Pharmaceutical compositions comprising alisporivir
IN2013MU03317A (pt)
WO2014122671A3 (en) Solid oral compositions of saxagliptin